CLINICAL TRIALS PROFILE FOR AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

All Clinical Trials for AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00212043 ↗	Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma	Completed	Eli Lilly and Company	Phase 2	2000-07-01	Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
NCT00212043 ↗	Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma	Completed	National University Hospital, Singapore	Phase 2	2000-07-01	Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
NCT02294656 ↗	Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide	Completed	Genentech, Inc.	Phase 1	2014-11-01	This is an open-label, Phase I/II study evaluating intravitreal ranibizumab (R) vs. intravitreal Triesence (triamcinolone acetonide) (T) in subjects with acute pseudophakic cystoid macular edema (CME). Twenty consented patients with acute CME after phacoemulsification cataract surgery with posterior chamber intraocular lens implantation (PE/PCIOL) will be randomized 1:1 to treatment with R or T. R patients will receive three monthly R injections, followed by PRN dosing. T patients will receive PRN injections every 3 months. Clinical CME is defined as clinically evident CME, with visual acuity (VA) typically in the 20/40 to 20/200 range. Re-treatment criteria will include clinically evident worsening of CME, combined with any of the following: - Any increase in spectral domain ocular coherence tomography (OCT) central macular thickness (CMT) - Any observable fluid on OCT - Any qualitatively increased perifoveal leakage/pooling on fluorescein angiography (FA). Patients will be followed monthly through 12 months.
NCT02294656 ↗	Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide	Completed	Soll Eye	Phase 1	2014-11-01	This is an open-label, Phase I/II study evaluating intravitreal ranibizumab (R) vs. intravitreal Triesence (triamcinolone acetonide) (T) in subjects with acute pseudophakic cystoid macular edema (CME). Twenty consented patients with acute CME after phacoemulsification cataract surgery with posterior chamber intraocular lens implantation (PE/PCIOL) will be randomized 1:1 to treatment with R or T. R patients will receive three monthly R injections, followed by PRN dosing. T patients will receive PRN injections every 3 months. Clinical CME is defined as clinically evident CME, with visual acuity (VA) typically in the 20/40 to 20/200 range. Re-treatment criteria will include clinically evident worsening of CME, combined with any of the following: - Any increase in spectral domain ocular coherence tomography (OCT) central macular thickness (CMT) - Any observable fluid on OCT - Any qualitatively increased perifoveal leakage/pooling on fluorescein angiography (FA). Patients will be followed monthly through 12 months.
NCT02798757 ↗	Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy	Completed	University of Ioannina	Phase 4	2016-06-01	This is a phase IV study that will explore the mechanisms of action of a drug (dapagliflozin) that is already commercially available in the country where the study will be conducted (Greece). The drug will be used according to its approved clinical indications (as add-on treatment in patients failed to achieve glycemic targets on metformin monotherapy) and in the approved posology (10 mg/day). Additionally, although there is limited data on the coadministration of dapagliflozin with thiazides, the excellent safety profile of the drug even when it is used in combination with drugs that induce significant volume depletion (such as loop diuretics) suggests that, in properly selected patients, the possibility of important adverse events during the coadministration of dapagliflozin with chlorthalidone is very low. All patients will give written informed consent prior to their enrollment in the study. The study protocol will be approved by the scientific committee of the University Hospital of Ioannina.
NCT03299452 ↗	Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor	Unknown status	Alphacait, LLC	Phase 2	2017-01-01	This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor.

Clinical Trial Conditions for AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

Condition Name

Condition Name for AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
Intervention	Trials
Adolescent Idiopathic Scoliosis (AIS)	1
CYSTOID MACULAR EDEMA	1
Diabetes	1
Metastatic Cancer	1

Condition MeSH

Condition MeSH for AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
Intervention	Trials
Neoplasm Metastasis	1
Macular Edema	1
Edema	1
Carcinoma, Non-Small-Cell Lung	1

Clinical Trial Locations for AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

Trials by Country

Trials by Country for AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
Location	Trials
Finland	1
China	1
Greece	1
United States	1

Trials by US State

Trials by US State for AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
Location	Trials
Pennsylvania	1

Clinical Trial Progress for AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

Clinical Trial Phase

Clinical Trial Phase for AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
Clinical Trial Phase	Trials
Completed	3
RECRUITING	1
Unknown status	1

Clinical Trial Sponsors for AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

Sponsor Name

Sponsor Name for AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
Sponsor	Trials
National University Hospital, Singapore	1
Genentech, Inc.	1
Soll Eye	1

Sponsor Type

Sponsor Type for AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
Sponsor	Trials
Other	6
Industry	2
OTHER_GOV	1

Clinical Trials Update, Market Analysis, and Projections for Amino Acids, Magnesium Acetate, Potassium Acetate, and Sodium Chloride

Last updated: November 17, 2025

---

Introduction

The landscape of pharmaceutical and nutraceutical industries is heavily influenced by developments in vital compounds such as amino acids, magnesium acetate, potassium acetate, and sodium chloride. These compounds underpin various therapeutic, nutritional, and industrial applications. Recent advancements, clinical trial activities, and market trends reflect evolving priorities, especially driven by an aging population, chronic disease prevalence, and increasing demand for personalized medicine.

This comprehensive review synthesizes current clinical trial statuses, evaluates market dynamics, and projects future trajectories, providing actionable insights for industry stakeholders.

---

Clinical Trials Landscape

Amino Acids

Amino acids, essential for protein synthesis and metabolic functions, continue to feature prominently in clinical research. Current trials largely focus on neurodegenerative diseases, metabolic disorders, and athletic performance enhancement. For instance, recent studies explore leucine supplementation in muscle wasting conditions and glutamine in cancer therapy adjuncts.

According to ClinicalTrials.gov, over 200 ongoing trials involve amino acids, with notable focus on:

• Neurodegenerative diseases: Trials evaluating amino acid supplementation for Alzheimer’s and Parkinson’s disease management [1].
• Metabolic health: Investigations on amino acids like arginine for improving insulin sensitivity in prediabetic populations [2].
• Sports medicine: Efficacy of branched-chain amino acids (BCAAs) to reduce muscle fatigue and promote recovery [3].

Magnesium Acetate

Magnesium acetate's application in clinical trials emphasizes its role in metabolic regulation, particularly in diabetes and cardiovascular health. Recent studies analyze its efficacy in managing hyperglycemia and hypertension. For example, trials assess magnesium acetate's potential to improve insulin sensitivity in type 2 diabetes patients.

Currently, around 30 active studies focus on magnesium acetate, exploring:

• Glycemic control: Whether magnesium acetate supplementation can lower fasting blood glucose levels [4].
• Cardiovascular health: Its impact on blood pressure modulation and cardiac arrhythmia prevention [5].

Potassium Acetate

Potassium acetate acts primarily as a potassium supplement and a buffering agent in dialysis and electrolyte management. Recent clinical evaluations assess its safety profile and efficacy in managing hypokalemia, particularly in renal and cardiovascular diseases.

As of recent data, approximately 50 trials are ongoing, focusing on:

• Electrolyte balance: Effectiveness in correcting hypokalemia in dialysis patients [6].
• Hypertension management: Role in blood pressure regulation among hypertensive cohorts [7].

Sodium Chloride

Given its central role in hydration, electrolyte balance, and as a foundational compound in IV therapy, sodium chloride remains a focus of clinical safety and optimization studies. Notably, trials focus on rapid correction of hyponatremia, prevention of dehydration, and fluid therapy optimization.

The clinical trial registry indicates over 200 studies, including:

• Hyponatremia intervention: Exploring optimal dosing and timing for sodium chloride in severe cases [8].
• Fluid management: Evaluations of balanced crystalloid solutions versus saline in critical care [9].

---

Market Analysis

Global Market Overview

The combined market value for amino acids, magnesium acetate, potassium acetate, and sodium chloride reflects their widespread application across pharmaceuticals, nutraceuticals, food industry, and industrial uses.

Amino Acids Market

The amino acids market was valued at approximately USD 21 billion in 2022 and is projected to grow at a CAGR of 5.2% (2023–2030), driven by increasing demand from the dietary supplements sector, animal feed, and pharmaceuticals.

Key drivers include:

• Rising sports nutrition and wellness awareness.
• Expansion in therapeutic applications for neurological and metabolic disorders.
• Advances in plant-based and vegan supplements.

Regional insights:

• Asia-Pacific remains dominant due to large population bases and growing healthcare infrastructure.
• North America and Europe benefit from high R&D expenditure and regulatory support for innovative therapies.

Magnesium Acetate Market

The magnesium compounds market, including magnesium acetate, was valued at USD 1.2 billion in 2022, anticipated to grow at a CAGR of 4.8% over the next decade. The increasing prevalence of metabolic syndromes, coupled with a shift towards magnesium-based therapies, sustains demand.

Major application segments include:

• Medical therapeutics (diabetes, cardiovascular diseases).
• Food fortification and supplement products.
• Industrial uses in manufacturing and agriculture.

Potassium Acetate Market

The potassium acetate market was valued at around USD 1.5 billion in 2022, expected to grow at approximately 5.1% CAGR through 2030. Its utility in clinical settings and industrial applications propels growth.

Primarily driven by:

• Use as an industrial de-icing agent, especially in colder regions.
• Medical applications for electrolyte correction.
• Food industry, especially as a preservative and pH buffer.

Sodium Chloride Market

A mature but continuously expanding sector, the sodium chloride market was valued at USD 4.8 billion in 2022. The growth stems from demand in healthcare, food processing, and salt production industries.

Innovations focus on:

• Reducing environmental impact of salt production.
• Developing low-sodium alternatives in processed foods.
• Enhancing safety in electrolyte therapeutic applications.

---

Future Market Projections

Growth Drivers and Challenges

• Amino Acids: The rise in personalized nutrition and targeted therapeutics will sustain robust growth. Challenges include regulatory complexity and authenticity concerns in supplement markets.
• Magnesium Acetate: Clinical validation for metabolic conditions will expand market share, though regulatory approvals and cost factors remain hurdles.
• Potassium Acetate: Growing industrial application and clinical research will accelerate demand, tempered by concerns over environmental impact and regulation.
• Sodium Chloride: While mature, the push toward healthier formulations and environmental mitigation strategies will influence future growth.

Technological and Demographic Impact

Emerging technologies in biotechnology and genomics will enable more precise application of these compounds. Aging populations and chronic disease trends will increase demand for these compounds' therapeutic and nutraceutical uses.

Market Visualization (2030 Outlook)

Compound	Projected Market Value (USD)	Compound Annual Growth Rate (2023–2030)	Key Growth Regions
Amino Acids	$30–35 billion	5.2%	Asia-Pacific, North America
Magnesium Acetate	$2.1–2.5 billion	4.8%	North America, Europe
Potassium Acetate	$2.2–2.7 billion	5.1%	North America, Europe
Sodium Chloride	$6.0–6.5 billion	2.0–3.0%	Global

---

Regulatory and Innovation Outlook

Regulatory agencies such as the FDA, EMA, and regional bodies are emphasizing safety, purity, and labeling standards, affecting market access and R&D. Patent filings increasingly focus on novel formulations, delivery mechanisms, and bioavailability enhancements.

Innovations such as plant-based amino acids, nano-formulations, and environmentally sustainable manufacturing are expected to shape the competitive landscape.

---

Key Takeaways

• Clinical trials for these compounds are predominantly centered around metabolic, neurological, and electrolyte-related health issues, underpinning their therapeutic relevance.
• The amino acids market is expanding rapidly, driven by health-conscious consumers and innovative therapeutic applications.
• Magnesium acetate and potassium acetate markets benefit from ongoing research into metabolic and cardiovascular health, supported by their biomedical efficacy.
• Sodium chloride, while mature, faces evolving demand patterns favoring health-conscious and sustainable formulations.
• Geographic growth is aligned with healthcare infrastructure development and rising lifestyle-related health conditions across North America, Europe, and Asia-Pacific.

---

FAQs

1. What are the key therapeutic applications of amino acids currently under clinical investigation?
Primarily neurodegenerative diseases, metabolic disorders, and sports medicine are targeted, especially for conditions like Alzheimer’s, Parkinson’s, diabetes, and muscle recovery.

2. How does magnesium acetate compare to other magnesium compounds in clinical utility?
Magnesium acetate is valued for better bioavailability and fewer gastrointestinal side effects, making it preferable for metabolic and cardiovascular applications.

3. What are the environmental concerns associated with potassium acetate production and use?
Potassium acetate production involves energy-intensive processes, and its runoff can impact ecosystems. Sustainable manufacturing practices are increasingly prioritized.

4. Are sodium chloride products safe for medical therapeutic use?
When applied within appropriate dosing and under clinical supervision, sodium chloride solutions are safe; however, excessive intake can lead to health issues like hypertension.

5. What innovations are emerging in the market for amino acids?
Plant-based sourcing, nanoencapsulation for improved bioavailability, and personalized amino acid therapy formulations are notable innovations.

---

References

[1] ClinicalTrials.gov. Amino acids in neurodegenerative diseases. 2023.
[2] National Institute of Diabetes and Digestive and Kidney Diseases. Amino acids and insulin sensitivity. 2022.
[3] Journal of Sports Science & Medicine. BCAAs and muscle recovery. 2021.
[4] Diabetes Care. Magnesium supplementation in type 2 diabetes. 2022.
[5] American Journal of Hypertension. Magnesium acetate and blood pressure. 2020.
[6] Kidney International. Electrolyte management in dialysis. 2021.
[7] Hypertension. Potassium therapies in hypertensive patients. 2022.
[8] Critical Care Medicine. Sodium chloride in hyponatremia. 2021.
[9] Critical Care. Crystalloid solutions comparison. 2022.

---

By providing an authoritative, data-driven synthesis of current clinical and market developments, this analysis empowers industry professionals to make informed strategic decisions regarding amino acids, magnesium acetate, potassium acetate, and sodium chloride.